La transformation stratégique soutient la performance de Roquette au premier semestre 2026

Roquette reported H1 2026 revenue of €2.586bn, up 9% year on year, and recurring EBITDA of €337m, up 18%, lifting the EBITDA margin by 101bps to 13.0%. Net income turned positive at €17m versus a €115m loss in H1 2025, while adjusted net income rose 44% to €61m and free cash flow improved to negative €54m from negative €150m. Net debt fell €530m to €1.86bn and leverage declined to 2.80x after a successful €600m perpetual hybrid-bond issuance, although like-for-like revenue and EBITDA each declined 2% amid commodity pricing pressure and competitive markets.

Analysis

The investable read-through is narrower than the headline implies: Roquette is privately held, and the supplied ticker BC is Brunswick, an unrelated marine company. There is therefore no direct listed-equity expression; the relevant public comparables are excipient and specialty-ingredient suppliers Ashland (ASH), Ingredion (INGR), Tate & Lyle (TATE.L) and DSM-Firmenich (DSFIR.AS). Roquette’s push toward higher-value pharma ingredients raises competitive intensity in oral-solid-dose excipients, where ASH has the most direct exposure, but it also validates that customers are paying for formulation performance rather than commodity starch inputs.

The key quality issue is that reported profitability and deleveraging are not equivalent to a clean organic turnaround. Acquisition mix, inventory release and hybrid-capital treatment can improve headline margins and leverage while cash conversion remains constrained by interest/coupon obligations, restructuring and integration spend. Over the next 1-3 months, evidence that pricing pressure in commodity-derived ingredients is stabilizing—and that North American manufacturing reliability improves—matters more than further cost-savings claims; failure would imply the portfolio is masking underlying erosion.

Contrarian view: the strategic premiumization narrative may be underappreciated if specialty pharma volumes can offset cyclicality in food ingredients, supporting a longer-duration rerating in listed peers with similar mix. Conversely, an industry-wide recovery in starch/polyol pricing would benefit INGR and TATE.L more directly because their earnings have greater operating leverage to commodity normalization, whereas Roquette’s current trajectory appears increasingly dependent on integration execution and cost action.

Key Decisions for Investors

• No action in BC: remove it from any Roquette-related event screen; Brunswick has no apparent operating linkage, so any reaction would be a data-mapping error.
• Watch ASH for a 1-3 month relative-value short trigger versus DSFIR.AS if ASH reports excipient price/volume pressure or loses cellulose-related share; use a 5-7% relative spread stop, as pharma-excipient demand resilience would invalidate the thesis.
• Prefer long INGR or TATE.L on confirmation of two consecutive months of improving European sweetener/starch pricing, paired against a broad staples ETF if needed. The payoff is operating leverage from commodity-margin normalization over 6-12 months; avoid entry until pricing data turns, since current competition can continue to compress spreads.
• For credit monitoring, track Roquette hybrid and senior-bond spreads where accessible rather than treating lower reported leverage as outright credit improvement. A sustained failure to convert second-half EBITDA into positive free cash flow, or renewed integration charges, would be the relevant spread-widening catalyst.